# A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT06010303** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 118 (actual)

## Conditions studied

- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

## Interventions

- **DRUG:** LBL-007
- **DRUG:** Tislelizumab
- **DRUG:** Chemotherapy Doublet

## Key facts

- **NCT ID:** NCT06010303
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-08
- **Primary completion:** 2025-05-30
- **Final completion:** 2026-05-23
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010303, "A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06010303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*